Nicotine Dependence, Tobacco Use Disorder
Conditions
Keywords
e-cigarettes, cannabis, treatment
Brief summary
The purpose of this study is to better understand tobacco outcomes using a commonly prescribed stop smoking medication (varenicline) and financial incentives for adults who also use cannabis. Varenicline is not FDA approved for e-cigarette cessation, but is FDA approved for cigarette cessation. Investigators are also interested in how cannabis/marijuana and tobacco interact during a tobacco quit attempt. All participants will receive e-cigarette cessation treatment for 12 weeks. To qualify, participants must be between the ages of 18-40 and use both e-cigarettes and cannabis. Participants do not need to be interested in quitting cannabis to qualify. This study is being conducted at three sites: the Medical University of South Carolina in Charleston, SC, Behavioral Health Services in Pickens, SC, and MUSC Lancaster in Lancaster, SC.
Detailed description
Cannabis co-use among tobacco users is exceedingly common and rates of co-use appear to be increasing among adults in the US, which is consistent with overall increases in cannabis use rates among US adults. Given the current cannabis landscape, further increases in cannabis use are likely and may result in continued increases in the co-use of cannabis and tobacco. Despite high rates of co-use, there is little consensus regarding treatment recommendations for this population and an understanding of the impact of co-use on successful cessation. The literature on the impact of co-use on tobacco cessation outcomes specifically has been mixed and fraught with limitations, including methodological variation, lack of biochemical verification to confirm cannabis use status and severity, and variations in study samples. Currently, no prospective studies have been conducted to evaluate the impact of cannabis use on tobacco cessation outcomes. Further, no studies have collected cannabis use changes during tobacco cessation treatment to assess for concurrent reductions, abstinence, or of greater concern, compensatory (i.e., increased) use as a result of tobacco reduction/abstinence. This study is a prospective 12-week tobacco cessation trial using established methods and outcomes typical of tobacco cessation trials, but specifically recruiting co-users of cannabis. The aims of this proposed study are to; Specific Aim 1. Compare rates of 7-day biochemically-confirmed e-cigarette abstinence with cigarette abstinence rates from the parent R37 co-use sample (as a historical controls). Specific Aim 2. Assess changes in cannabis use during e-cigarette cessation treatment among the new sample of participants enrolled in this extension. Specific Aim 3. Assess for a dose-dependent impact of cannabis co-use severity on e-cigarette cessation. Specific Aim 4. Characterize and compare patterns of co-use among the e-cigarette sample to those using cigarettes (parent R37).
Interventions
DRUGVarenicline Pill
In this study, all participants will be administered active medication for a 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
BEHAVIORALContingency management
Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on e-cigarette abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
BEHAVIORALCounseling
Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study.
Sponsors
National Cancer Institute (NCI)
Medical University of South Carolina
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Between the ages of 18 and 40 years old * Use e-cigarettes daily or near daily in the past month * Must submit a positive instant-read urine cotinine test at screening (≥ 200 ng/ml) * Be interested in quitting use of e-cigarettes * Must be willing to take varenicline for the standard 12-week course of treatment * Self-reported use of cannabis on at least 10 out of the past 30 days or must submit a positive qualitative urinary cannabinoid test at screening (\> 50 ng/ml)
Exclusion criteria
* Any serious or unstable medical/psychiatric disorder (including severe substance use disorders, other than cannabis or tobacco use disorders) in the past three months that may interfere with study performance * Use of cigarettes on 10+ days in the past 30 * Currently pregnant or breastfeeding * Current use of medications with smoking cessation efficacy * Use of any medications that would interfere with varenicline
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 7-day point prevalence tobacco abstinence at the end of treatment (Week 12) | Final 7 days of treatment (Week 12) | 7-day point prevalence abstinence from e-cigarettes at the end of treatment (Week 12) will be assessed via biochemical verification (urinary cotinine; ng/ml) and will be compared to cigarette abstinence rates from the parent study (as historical controls) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in cannabis use during e-cigarette cessation treatment | Final 4 weeks of study treatment (Weeks 8-12) | Cannabis use rates (based on urinary cannabinoids \[ng/ml\]) during the final 4 weeks of tobacco treatment (Weeks 8-12) will be assessed. |
| Cannabis co-use severity on e-cigarette abstinence rates | Final 7 days of treatment (Week 12) | Assess for a dose-dependent impact of cannabis co-use severity on e-cigarette cessation. |
Countries
United States
Contacts
Primary ContactElizabeth Chapman, MA, LPC, LAC, AADC
Outcome results
None listed